198 related articles for article (PubMed ID: 32636238)
1. Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency.
Pang X; Qian J; Jin H; Zhang L; Lin L; Wang Y; Lei Y; Zhou Z; Li M; Zhang H
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636238
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Hu ZI; Hellmann MD; Wolchok JD; Vyas M; Shia J; Stadler ZK; Diaz LA; O'Reilly EM
J Immunother Cancer; 2018 Nov; 6(1):127. PubMed ID: 30458888
[TBL] [Abstract][Full Text] [Related]
3. Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer.
Tsang ES; Walker EJ; Carnevale J; Fisher GA; Ko AH
Immunotherapy; 2021 Oct; 13(15):1249-1254. PubMed ID: 34338034
[TBL] [Abstract][Full Text] [Related]
4. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Jono M; Kinehara Y; Utsu Y; Tamura Y; Koseto M; Murakami T; Uota A; Ninomiya R; Komo S; Sumitani S; Sato B; Kasayama S; Tachibana I
Intern Med; 2020 Feb; 59(4):569-572. PubMed ID: 31666468
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report.
Obayashi M; Shibasaki Y; Koakutsu T; Hayashi Y; Shoji T; Hirayama K; Yamazaki M; Takayanagi Y; Shibata H; Nakamura M; Maruo H
BMC Gastroenterol; 2020 Jul; 20(1):220. PubMed ID: 32652936
[TBL] [Abstract][Full Text] [Related]
7. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature.
Qiu L; Liu C; Li H
Anticancer Drugs; 2024 Mar; 35(3):263-270. PubMed ID: 38194502
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
11. Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
Patil NR; Khan GN
Am J Case Rep; 2020 Jul; 21():e923803. PubMed ID: 32658872
[TBL] [Abstract][Full Text] [Related]
12. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
14. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Yarchoan M; Huang CY; Zhu Q; Ferguson AK; Durham JN; Anders RA; Thompson ED; Rozich NS; Thomas DL; Nauroth JM; Rodriguez C; Osipov A; De Jesus-Acosta A; Le DT; Murphy AG; Laheru D; Donehower RC; Jaffee EM; Zheng L; Azad NS
Cancer Med; 2020 Feb; 9(4):1485-1494. PubMed ID: 31876399
[TBL] [Abstract][Full Text] [Related]
16. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.
Sachdeva M; Ngoi NYL; Lim D; Poon MLM; Thian YL; Lim YW; Lim SE; Tong P; Lum JHY; Ng J; Ilancheran A; Domingo EJ; Low JJH; Tan DSP
Onco Targets Ther; 2021; 14():3921-3928. PubMed ID: 34234460
[TBL] [Abstract][Full Text] [Related]
18. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab.
Kiyomiya M; Fukuda K; Shimazu K; Yoshida T; Taguchi D; Shinozaki H; Nanjyo H; Shibata H
Jpn J Clin Oncol; 2023 Mar; 53(3):270-274. PubMed ID: 36484308
[TBL] [Abstract][Full Text] [Related]
19. Combined Antiangiogenic Therapy and Immunotherapy Is Effective for Pancreatic Cancer With Mismatch Repair Proficiency but High Tumor Mutation Burden: A Case Report.
Chen M; Yang S; Fan L; Wu L; Chen R; Chang J; Hu J
Pancreas; 2019 Oct; 48(9):1232-1236. PubMed ID: 31609933
[TBL] [Abstract][Full Text] [Related]
20. Multiple Brain Metastases from Pancreatic Adenocarcinoma Manifesting with Simultaneous Intratumoral Hemorrhages.
Matsuo S; Amano T; Kawauchi S; Nakamizo A
World Neurosurg; 2019 Mar; 123():221-225. PubMed ID: 30579022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
